Quality Of Life In Heart Patients- The Way You Measure Drives The Results

Published Jan 23, 2014
Gent, Belgium - Pain, anxiety, and functional or social limitations can cause an impaired Health-Related Quality of Life (HRQoL) in heart patients. Several measures exist to assess HRQoL, with some of them, such as the EQ-5D and the SF-6D (derived from the SF-12), generating a single utility measure of health. These are particularly useful in the calculation of cost-effectiveness ratio’s (ICER), for computing health benefits expressed in quality adjusted life years (QALYs). The utility outcomes differ depending on the tool used. Whereas the main disadvantage of the EQ-5D is its ceiling effect, the potential advantages of SF-12 might disappear when converting the outcomes into an SF-6D utility score, due to the small differences between patients. Researchers from Ghent University investigated how the HRQoL measure affects the outcome. Both EQ-5D and SF-12 outcomes in a sample of 7472 coronary patients from 20 European countries (the EUROASPIRE III survey: European survey of cardiovascular disease prevention and diabetes) were compared. In their study, “EQ-5D Versus SF-12 in Coronary Patients: Are They Interchangeable?” published in Value in Health, the researchers found that although the EQ-5D and SF-6D are significantly correlated, large differences between the two instruments were observed. The median utility values differed significantly from each other with lower SF-6D outcomes compared to the EQ-5D results across all countries. In contrast to the SF-6D, an important ceiling effect was found on the EQ-5D instrument. Especially the mental component does not seem to be adequately captured by the EQ-5D instrument. Furthermore, patients with worse EQ-5D outcomes were more likely to have better SF-6D results, whereas patients with better EQ-5D outcomes were more likely to have worse SF-6D results. Delphine De Smedt, MSc, from Ghent University, lead author on the study, states, “The way you measure HRQoL drives the results. EQ-5D and SF-6D utility estimates in coronary patients are not interchangeable. Awareness concerning this issue should be raised among researchers performing cost-effectiveness analyses.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×